{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:21:44Z","timestamp":1794565304255,"version":"4.9.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2287-y","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T13:39:39Z","timestamp":1488375579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Reactivation of occult HBV infection in an HIV\/HCV Co-infected patient successfully treated with sofosbuvir\/ledipasvir: a case report and review of the literature"],"prefix":"10.1186","volume":"17","author":[{"given":"Gabriele","family":"Fabbri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Mastrorosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vergori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Mazzotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Pinnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Grisetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Zaccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Ammassari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,1]]},"reference":[{"key":"2287_CR1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s15010-016-0891-1","volume":"44","author":"C Sagnelli","year":"2016","unstructured":"Sagnelli C, Macera M, Pisaturo M, Zampino R, Coppola M, Sagnelli E. Occult HBV infection in the oncohematological setting. Infection. 2016;44:575\u201382.","journal-title":"Infection"},{"key":"2287_CR2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4254\/wjh.v6.i6.384","volume":"6","author":"E Sagnelli","year":"2014","unstructured":"Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol. 2014;6:384\u201393.","journal-title":"World J Hepatol."},{"key":"2287_CR3","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3109\/00365520903329585","volume":"44","author":"A Potthoff","year":"2009","unstructured":"Potthoff A, Berg T, Wedemeyer H, HEP-NET B\/C Coinfection Study Group. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand J Gastroenterol. 2009;44:1487\u201390.","journal-title":"Scand J Gastroenterol"},{"key":"2287_CR4","first-page":"222","volume":"18","author":"V Soriano","year":"2016","unstructured":"Soriano V. Reactivation of Hepatitis B in HIV Patients Treated for Hepatitis C. AIDS Rev. 2016;18:222\u20133.","journal-title":"AIDS Rev."},{"key":"2287_CR5","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1093\/jac\/dkw203","volume":"71","author":"C Hawkins","year":"2016","unstructured":"Hawkins C, Grant J, Ammerman LR, Palella F, Mclaughlin M, Green R, et al. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV\/HCV-coinfected patients: a real-world perspective. J Antimicrob Chemother. 2016;71:2642\u20135.","journal-title":"J Antimicrob Chemother."},{"key":"2287_CR6","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/cid\/civ474","volume":"61","author":"JM Collins","year":"2015","unstructured":"Collins JM, Raphael KL, Terry C, Cartwright EJ, Pillai A, Anania FA, et al. Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. Clin Infect Dis. 2015;61:1304\u20136.","journal-title":"Clin Infect Dis."},{"key":"2287_CR7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcv.2016.02.026","volume":"78","author":"A Monte De","year":"2016","unstructured":"De Monte A, Courjon J, Anty R, Cua E, Naqvi A, Mondain V, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016;78:27\u201330.","journal-title":"J Clin Virol."},{"key":"2287_CR8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s12328-016-0657-4","volume":"9","author":"K Hayashi","year":"2016","unstructured":"Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Nishimura D, et al. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis? Clin J Gastroenterol. 2016;9:252\u20136.","journal-title":"Clin J Gastroenterol."},{"key":"2287_CR9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/hepr.12578","volume":"46","author":"H Takayama","year":"2016","unstructured":"Takayama H, Sato T, Ikeda F, Fujiki S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus\/hepatitis C virus co-infection. Hepatol Res. 2016;46:489\u201391.","journal-title":"Hepatol Res."},{"key":"2287_CR10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13256-015-0630-8","volume":"9","author":"AR Ende","year":"2015","unstructured":"Ende AR, Kim NH, Yeh MM, Harper J, Landis CS. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep. 2015;9:164.","journal-title":"J Med Case Rep."},{"key":"2287_CR11","unstructured":"FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm522932.htm . Accessed 10 Apr 2016."},{"key":"2287_CR12","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/cid\/ciw507","volume":"63","author":"MS Sulkowski","year":"2016","unstructured":"Sulkowski MS, Chuang WL, Kao JH, Yang JC, Gao B, Brainard DM, et al. No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection. Clin Infect Dis. 2016;63:1202\u20134.","journal-title":"Clin Infect Dis."},{"key":"2287_CR13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3851\/IMP3066","volume":"21","author":"EJ Gane","year":"2016","unstructured":"Gane EJ, Hyland RH, An D, Svarovskaia ES, Brainard D, McHutchison JG. Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV. Antivir Ther. 2016;21:605\u20139.","journal-title":"Antivir Ther."},{"key":"2287_CR14","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bbmt.2007.05.009","volume":"13","author":"P Kaloyannidis","year":"2007","unstructured":"Kaloyannidis P, Batsis I, Yannaki E, et al. Allografted recipients immunized against hepatitis B virus are at high risk of gradual surface antibody (HbsAb) disappearance post transplant, regardless of adoptive immunity transfer. Biol Blood Marrow Transplant. 2007;13:1049\u201356.","journal-title":"Biol Blood Marrow Transplant."},{"key":"2287_CR15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jcv.2005.10.006","volume":"35","author":"E Sagnelli","year":"2006","unstructured":"Sagnelli E, Coppola N, Marrocco C, Onofrio M, Sagnelli C, Coviello G, et al. Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course. J Clin Virol. 2006;35:317\u201320.","journal-title":"J Clin Virol"},{"key":"2287_CR16","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.22794","volume":"49","author":"E Sagnelli","year":"2009","unstructured":"Sagnelli E, Coppola N, Pisaturo M, Masiello A, Tonziello G, Sagnelli C, et al. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology. 2009;49:1090\u20137.","journal-title":"Hepatology"},{"key":"2287_CR17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1074\/jbc.M204241200","volume":"278","author":"SY Chen","year":"2003","unstructured":"Chen SY, Kao CF, Chen CM, Shih CM, Hsu MJ, Chao CH, et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem. 2003;278:591\u2013607.","journal-title":"J Biol Chem."},{"key":"2287_CR18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0168-8278(02)00296-9","volume":"37","author":"CG Sch\u00fcttler","year":"2002","unstructured":"Sch\u00fcttler CG, Fiedler N, Schmidt K, Repp R, Gerlich WH, Schaefer S. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol. 2002;37:855\u201362.","journal-title":"J Hepatol."},{"key":"2287_CR19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/hep.510250338","volume":"25","author":"C Pasquinelli","year":"1997","unstructured":"Pasquinelli C, Shoenberger JM, Chung J, Chang KM, Guidotti LG, Selby M, et al. Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology. 1997;25:719\u201327.","journal-title":"Hepatology"},{"key":"2287_CR20","doi-asserted-by":"crossref","first-page":"10072","DOI":"10.1128\/JVI.00541-07","volume":"81","author":"H Guo","year":"2007","unstructured":"Guo H, Zhou T, Jiang D, Cuconati A, Xiao GH, Block TM, et al. Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway. J Virol. 2007;81:10072\u201380.","journal-title":"J Virol"},{"key":"2287_CR21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4254\/wjh.v7.i3.498","volume":"7","author":"K Song","year":"2015","unstructured":"Song K, Han C, Dash S, Balart LA, Wu T. MiR-122 in hepatitis B virus and hepatitis C virus dual infection. World J Hepatol. 2015;7:498\u2013506.","journal-title":"World J Hepatol."},{"key":"2287_CR22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s11904-015-0275-7","volume":"12","author":"V Soriano","year":"2015","unstructured":"Soriano V, Labarga P, de Mendoza C, Pe\u00f1a JM, Fern\u00e1ndez-Montero JV, Ben\u00edtez L, et al. Emerging challenges in managing hepatitis B in HIV patients. Curr HIV\/AIDS Rep. 2015;12:344\u201352.","journal-title":"Curr HIV\/AIDS Rep."},{"key":"2287_CR23","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jiac.2016.01.004","volume":"22","author":"C Lepelletier","year":"2016","unstructured":"Lepelletier C, Salmona M, Ber\u00e7ot B, Maylin S, Sellier PO. First description of past Hepatitis B Virus infection acute reactivation occurring in a Human Immunodeficiency Virus infected patient as manifestation of immune reconstitution inflammatory syndrome. J Infect Chemother. 2016;22:490\u20134.","journal-title":"J Infect Chemother."},{"key":"2287_CR24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jcv.2014.04.021","volume":"60","author":"CS Coffin","year":"2014","unstructured":"Coffin CS, Mulrooney-Cousins PM, Osiowy C, van der Meer F, Nishikawa S, Michalak TI, et al. Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV\/HIV therapy. J Clin Virol. 2014;60:347\u201353.","journal-title":"J Clin Virol."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2287-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T22:21:31Z","timestamp":1750026091000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2287-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2287"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2287-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,1]]},"article-number":"182"}}